A phase 2 study of Y-90-Ibritumomab tiuxetan (Y-90-Zevalin (R)) in relapsed/refractory non-Hodgkin's lymphoma: Preliminary report of the Argentinean cooperative group.
- Resource Type
- Journal
- Source
BLOOD ; NOV 16 2006, 108 11, p254B-p254B, 1p.- Subject
- Language
- English
- ISSN
- 00064971